Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TARS 
Tarsus Pharmaceuticals Inc (TARS)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: TARS (4-star) is a STRONG-BUY. BUY since 5 days. Profits (13.15%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $73.88
1 Year Target Price $73.88
| 6 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 185.54% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.29B USD | Price to earnings Ratio - | 1Y Target Price 73.88 |
Price to earnings Ratio - | 1Y Target Price 73.88 | ||
Volume (30-day avg) 8 | Beta 0.79 | 52 Weeks Range 25.14 - 57.28 | Updated Date 08/15/2025 |
52 Weeks Range 25.14 - 57.28 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.38 | Actual -0.48 |
Profitability
Profit Margin -31.13% | Operating Margin (TTM) -21.61% |
Management Effectiveness
Return on Assets (TTM) -14.06% | Return on Equity (TTM) -31.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1976774698 | Price to Sales(TTM) 7.73 |
Enterprise Value 1976774698 | Price to Sales(TTM) 7.73 | ||
Enterprise Value to Revenue 6.69 | Enterprise Value to EBITDA -3.23 | Shares Outstanding 42214100 | Shares Floating 30507290 |
Shares Outstanding 42214100 | Shares Floating 30507290 | ||
Percent Insiders 3.24 | Percent Institutions 116.79 |
Upturn AI SWOT
Tarsus Pharmaceuticals Inc
Company Overview
History and Background
Tarsus Pharmaceuticals, Inc. was founded in 2016. It is a late clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutic candidates to address unmet needs in ophthalmic conditions, starting with Demodex blepharitis.
Core Business Areas
- Ophthalmology: Focuses on developing and commercializing therapies for ophthalmic conditions, particularly Demodex blepharitis. Their leading product is XDEMVY.
Leadership and Structure
Dr. Bobby Azamian is the Chairman and CEO. The company has a typical structure with departments focusing on R&D, commercialization, and finance.
Top Products and Market Share
Key Offerings
- XDEMVY: XDEMVY (lotilaner ophthalmic solution) 0.25% is the first and only FDA-approved treatment for Demodex blepharitis. The market share is growing as it's a new treatment. Competitors include off-label treatments like tea tree oil and eyelid scrubs, as well as other future prescription treatments.
Market Dynamics
Industry Overview
The ophthalmic pharmaceutical market is large and growing, driven by an aging population and increasing prevalence of eye diseases.
Positioning
Tarsus is positioned as an innovator in the treatment of Demodex blepharitis with XDEMVY, a prescription product filling an unmet need.
Total Addressable Market (TAM)
The TAM for Demodex blepharitis treatment is estimated to be substantial, given the high prevalence of the condition. Tarsus is uniquely positioned to capture a significant share of this market with XDEMVY.
Upturn SWOT Analysis
Strengths
- FDA-approved product (XDEMVY)
- First-mover advantage in Demodex blepharitis treatment
- Strong intellectual property protection
- Experienced management team
Weaknesses
- Sole reliance on XDEMVY
- Limited commercial history
- Potential for competition from generics or other treatments
- Need for strong sales and marketing execution
Opportunities
- Expanding XDEMVY's market reach
- Developing new ophthalmic products
- Acquiring or partnering with other companies
- Addressing other indications for XDEMVY
Threats
- Competition from other treatments
- Pricing pressure from payers
- Regulatory changes
- Unfavorable clinical trial results for future products
Competitors and Market Share
Key Competitors
- ALVR
- MRK
- PFE
Competitive Landscape
Tarsus has a competitive advantage with XDEMVY as the only FDA-approved treatment for Demodex blepharitis. However, they face competition from established pharmaceutical companies in the broader ophthalmology market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on clinical development and regulatory approval of XDEMVY.
Future Projections: Future growth is projected to be driven by increased sales of XDEMVY and potential development of new products.
Recent Initiatives: Recent initiatives include expanding the sales force, increasing marketing efforts, and conducting post-marketing studies of XDEMVY.
Summary
Tarsus Pharmaceuticals is a company with a groundbreaking treatment, XDEMVY, for Demodex blepharitis. The primary strength lies in being the only FDA-approved product for this condition. However, its sole product dependence and need to aggressively expand its market presence are points to watch. Future expansion into new markets could boost performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Tarsus Pharmaceuticals Investor Relations
- FDA Website
- Analyst Reports (where available)
Disclaimers:
This information is for illustrative purposes only and does not constitute financial advice. Market share data is estimated and may not be precise. Financial data is not provided and users should consult official financial reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tarsus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Irvine, CA, United States | ||
IPO Launch date 2020-10-16 | Co-Founder, President, CEO & Chairman Dr. Bobak R. Azamian M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 323 | Website https://www.tarsusrx.com |
Full time employees 323 | Website https://www.tarsusrx.com | ||
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company develops lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.